Discovery of novel diarylamides as orally active diuretics targeting urea transporters

Shun Zhang,Yan Zhao,Shuyuan Wang,Min Li,Yue Xu,Jianhua Ran,Xiaoqiang Geng,Jinzhao He,Jia Meng,Guangying Shao,Hong Zhou,Zemei Ge,Guangping Chen,Runtao Li,Baoxue Yang
DOI: https://doi.org/10.1016/j.apsb.2020.06.001
IF: 14.903
2021-01-01
Acta Pharmaceutica Sinica B
Abstract:<p>Urea transporters (UT) play a vital role in the mechanism of urine concentration and are recognized as novel targets for the development of salt-sparing diuretics. Thus, UT inhibitors are promising for development as novel diuretics. In the present study, a novel UT inhibitor with a diarylamide scaffold was discovered by high-throughput screening. Optimization of the inhibitor led to the identification of a promising preclinical candidate, <em>N</em>-[4-(acetylamino)phenyl]-5-nitrofuran-2-carboxamide (<strong>1H</strong>), with excellent <em>in vitro</em> UT inhibitory activity at the submicromolar level The half maximal inhibitory concentrations of <strong>1H</strong> against UT-B in mouse, rat, and human erythrocyte were 1.60, 0.64, and 0.13 μmol/L, respectively. Further investigation suggested that 8 μmol/L <strong>1H</strong> more powerfully inhibited UT-A1 at a rate of 86.8% than UT-B at a rate of 73.9% in MDCK cell models. Most interestingly, we found for the first time that oral administration of <strong>1H</strong> at a dose of 100 mg/kg showed superior diuretic effect <em>in vivo</em> without causing electrolyte imbalance in rats. Additionally, <strong>1H</strong> did not exhibit apparent toxicity <em>in vivo</em> and <em>in vitro</em>, and possessed favorable pharmacokinetic characteristics. <strong>1H</strong> shows promise as a novel diuretic to treat hyponatremia accompanied with volume expansion and may cause few side effects.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?